S&P 500   4,685.01 (+2.03%)
DOW   35,759.76 (+1.51%)
QQQ   395.66 (+2.45%)
AAPL   170.66 (+3.23%)
MSFT   333.01 (+2.09%)
FB   324.35 (+2.04%)
GOOGL   2,922.85 (+2.09%)
AMZN   3,506.43 (+2.31%)
TSLA   1,049.67 (+4.03%)
NVDA   312.41 (+4.01%)
BABA   125.81 (+1.79%)
NIO   33.36 (+3.15%)
CGC   10.63 (+4.73%)
AMD   142.51 (+2.48%)
GE   97.90 (+1.97%)
MU   86.00 (+4.31%)
T   23.24 (-0.17%)
F   19.94 (+3.75%)
DIS   151.36 (+0.66%)
PFE   52.00 (+1.01%)
AMC   31.15 (+8.20%)
ACB   6.24 (+4.52%)
BA   210.10 (+2.05%)
S&P 500   4,685.01 (+2.03%)
DOW   35,759.76 (+1.51%)
QQQ   395.66 (+2.45%)
AAPL   170.66 (+3.23%)
MSFT   333.01 (+2.09%)
FB   324.35 (+2.04%)
GOOGL   2,922.85 (+2.09%)
AMZN   3,506.43 (+2.31%)
TSLA   1,049.67 (+4.03%)
NVDA   312.41 (+4.01%)
BABA   125.81 (+1.79%)
NIO   33.36 (+3.15%)
CGC   10.63 (+4.73%)
AMD   142.51 (+2.48%)
GE   97.90 (+1.97%)
MU   86.00 (+4.31%)
T   23.24 (-0.17%)
F   19.94 (+3.75%)
DIS   151.36 (+0.66%)
PFE   52.00 (+1.01%)
AMC   31.15 (+8.20%)
ACB   6.24 (+4.52%)
BA   210.10 (+2.05%)
S&P 500   4,685.01 (+2.03%)
DOW   35,759.76 (+1.51%)
QQQ   395.66 (+2.45%)
AAPL   170.66 (+3.23%)
MSFT   333.01 (+2.09%)
FB   324.35 (+2.04%)
GOOGL   2,922.85 (+2.09%)
AMZN   3,506.43 (+2.31%)
TSLA   1,049.67 (+4.03%)
NVDA   312.41 (+4.01%)
BABA   125.81 (+1.79%)
NIO   33.36 (+3.15%)
CGC   10.63 (+4.73%)
AMD   142.51 (+2.48%)
GE   97.90 (+1.97%)
MU   86.00 (+4.31%)
T   23.24 (-0.17%)
F   19.94 (+3.75%)
DIS   151.36 (+0.66%)
PFE   52.00 (+1.01%)
AMC   31.15 (+8.20%)
ACB   6.24 (+4.52%)
BA   210.10 (+2.05%)
S&P 500   4,685.01 (+2.03%)
DOW   35,759.76 (+1.51%)
QQQ   395.66 (+2.45%)
AAPL   170.66 (+3.23%)
MSFT   333.01 (+2.09%)
FB   324.35 (+2.04%)
GOOGL   2,922.85 (+2.09%)
AMZN   3,506.43 (+2.31%)
TSLA   1,049.67 (+4.03%)
NVDA   312.41 (+4.01%)
BABA   125.81 (+1.79%)
NIO   33.36 (+3.15%)
CGC   10.63 (+4.73%)
AMD   142.51 (+2.48%)
GE   97.90 (+1.97%)
MU   86.00 (+4.31%)
T   23.24 (-0.17%)
F   19.94 (+3.75%)
DIS   151.36 (+0.66%)
PFE   52.00 (+1.01%)
AMC   31.15 (+8.20%)
ACB   6.24 (+4.52%)
BA   210.10 (+2.05%)
NASDAQ:EVLO

Evelo Biosciences Stock Forecast, Price & News

$8.94
+0.55 (+6.56%)
(As of 12/7/2021 10:09 AM ET)
Add
Compare
Today's Range
$8.70
$8.97
50-Day Range
$6.78
$12.00
52-Week Range
$4.88
$19.93
Volume
800 shs
Average Volume
260,581 shs
Market Capitalization
$477.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.57
30 days | 90 days | 365 days | Advanced Chart
Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Evelo Biosciences logo

About Evelo Biosciences

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVLO
Fax
N/A
Employees
2,018
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.62 per share

Profitability

Net Income
$-93.67 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
50,199,000
Market Cap
$477.93 million
Optionable
Not Optionable

Company Calendar

Last Earnings
10/27/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

631st out of 1,394 stocks

Pharmaceutical Preparations Industry

295th out of 673 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

Is Evelo Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Evelo Biosciences stock.
View analyst ratings for Evelo Biosciences
or view top-rated stocks.

How has Evelo Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EVLO stock has increased by 103.7% and is now trading at $8.90.
View which stocks have been most impacted by COVID-19
.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Evelo Biosciences
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) posted its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.09. During the same quarter in the previous year, the firm posted ($0.45) earnings per share.
View Evelo Biosciences' earnings history
.

What price target have analysts set for EVLO?

6 brokerages have issued 1-year price objectives for Evelo Biosciences' shares. Their forecasts range from $12.00 to $41.50. On average, they anticipate Evelo Biosciences' stock price to reach $21.92 in the next twelve months. This suggests a possible upside of 146.3% from the stock's current price.
View analysts' price targets for Evelo Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:
  • Simba Gill, President, Chief Executive Officer & Director
  • Luca Scavo, Chief Financial Officer, Treasurer & Senior VP
  • Mark Bodmer, Chief Scientific Officer, President-R&D
  • Andrea Itano, Senior Vice President & Head-Research
  • Duncan McHale, Chief Medical Officer

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an initial public offering (IPO) on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Credit Suisse AG (6.19%), BlackRock Inc. (3.44%), State of Michigan Retirement System (2.06%), Geode Capital Management LLC (0.97%), Millennium Management LLC (0.00%) and Citadel Advisors LLC (0.00%). Company insiders that own Evelo Biosciences stock include David R Epstein, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends for Evelo Biosciences
.

Which major investors are selling Evelo Biosciences stock?

EVLO stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, California State Teachers Retirement System, Marshall Wace LLP, New York State Common Retirement Fund, The Manufacturers Life Insurance Company , BlackRock Inc., and Larson Financial Group LLC.
View insider buying and selling activity for Evelo Biosciences
or view top insider-selling stocks.

Which major investors are buying Evelo Biosciences stock?

EVLO stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Credit Suisse AG, State of Michigan Retirement System, Citadel Advisors LLC, Belvedere Trading LLC, Cinctive Capital Management LP, Geode Capital Management LLC, and Morgan Stanley. Company insiders that have bought Evelo Biosciences stock in the last two years include David R Epstein, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Evelo Biosciences
or or view top insider-buying stocks.

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $8.90.

How much money does Evelo Biosciences make?

Evelo Biosciences has a market capitalization of $475.79 million. The company earns $-93.67 million in net income (profit) each year or ($2.39) on an earnings per share basis.

How many employees does Evelo Biosciences have?

Evelo Biosciences employs 2,018 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

Where are Evelo Biosciences' headquarters?

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at (617) 577-0300 or via email at [email protected].


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.